Literature DB >> 15664652

Internal and surface subpopulations of the major surface protease (MSP) of Leishmania chagasi.

Chaoqun Yao1, Jiwen Luo, Christine Hsiao, John E Donelson, Mary E Wilson.   

Abstract

Major surface protease (MSP) facilitates Leishmania promastigote evasion of complement-mediated lysis in the mammalian host and enhances host macrophage phagocytosis of the promastigotes. We previously showed that the steady-state abundance of MSP protein increases 14-fold during in vitro cultivation of L. chagasi promastigotes from logarithmic to stationary phase, despite the fact that the total amount of MSP mRNA does not increase. Furthermore, 10 major MSP isoforms are differentially expressed in different promastigote growth phases, and attenuation of parasites by long-term in vitro cultivation influences MSP isoform expression. Herein, we report that although about two-thirds of newly synthesized MSP becomes surface localized, the rest of the MSP does not reach the promastigote surface. This internal MSP is stable without detectable decrease in abundance up to 6 days after biosynthesis. Furthermore, surface-localized MSP is released at different rates from logarithmic and stationary phase virulent Leishmania promastigotes. These data are consistent with the hypothesis that the major mechanism regulating MSP abundance is the rate of loss of surface-localized MSP from the promastigote surface, and that internally localized MSP is very stable.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15664652     DOI: 10.1016/j.molbiopara.2004.11.005

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  9 in total

1.  Internal and surface-localized major surface proteases of Leishmania spp. and their differential release from promastigotes.

Authors:  Chaoqun Yao; John E Donelson; Mary E Wilson
Journal:  Eukaryot Cell       Date:  2007-08-10

2.  Proteomic examination of Leishmania chagasi plasma membrane proteins: Contrast between avirulent and virulent (metacyclic) parasite forms.

Authors:  Chaoqun Yao; Yalan Li; John E Donelson; Mary E Wilson
Journal:  Proteomics Clin Appl       Date:  2009-11-11       Impact factor: 3.494

3.  Leishmania chagasi: a tetracycline-inducible cell line driven by T7 RNA polymerase.

Authors:  Chaoqun Yao; Jiwen Luo; Chia-Hung Christine Hsiao; John E Donelson; Mary E Wilson
Journal:  Exp Parasitol       Date:  2007-01-19       Impact factor: 2.011

4.  Reduced hamster usage and stress in propagating Leishmania chagasi promastigotes using cryopreservation and saphenous vein inoculation.

Authors:  Soi Meng Lei; Amanda E Ramer-Tait; Rebecca R Dahlin-Laborde; Kathleen Mullin; Jeffrey K Beetham
Journal:  J Parasitol       Date:  2010-02       Impact factor: 1.276

5.  The major surface protease (MSP or GP63) in the intracellular amastigote stage of Leishmania chagasi.

Authors:  Chia-Hung Christine Hsiao; Chaoqun Yao; Patricia Storlie; John E Donelson; Mary E Wilson
Journal:  Mol Biochem Parasitol       Date:  2007-10-30       Impact factor: 1.759

Review 6.  Major surface protease of trypanosomatids: one size fits all?

Authors:  Chaoqun Yao
Journal:  Infect Immun       Date:  2009-10-26       Impact factor: 3.441

7.  Leishmania chagasi: homogenous metacyclic promastigotes isolated by buoyant density are highly virulent in a mouse model.

Authors:  Chaoqun Yao; Yani Chen; Bayan Sudan; John E Donelson; Mary E Wilson
Journal:  Exp Parasitol       Date:  2007-07-13       Impact factor: 2.011

8.  Attenuation of Leishmania infantum chagasi metacyclic promastigotes by sterol depletion.

Authors:  Chaoqun Yao; Upasna Gaur Dixit; Jason H Barker; Lynn M Teesch; Laurie Love-Homan; John E Donelson; Mary E Wilson
Journal:  Infect Immun       Date:  2013-04-29       Impact factor: 3.441

Review 9.  Comparative genomics: from genotype to disease phenotype in the leishmaniases.

Authors:  Deborah F Smith; Christopher S Peacock; Angela K Cruz
Journal:  Int J Parasitol       Date:  2007-06-23       Impact factor: 3.981

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.